SWISS drug ingredients maker Lonza Group is maintaining its full-year outlook amid positive momentum in its core healthcare businesses and headwinds in its speciality ingredients segment, the...

SWISS drug ingredients maker Lonza Group is maintaining its full-year outlook amid positive momentum in its core healthcare businesses and headwinds in its speciality ingredients segment, the...